Mauna Kea Technologies S.A. (MKEAF)
Mauna Kea Technologies S.A. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Paris, FR. The stock last traded at $0.37, up 0.00% on the session, giving a market capitalisation of $25.9M. On trailing twelve-month figures it carries a trailing P/E of 7.45, a net margin of 117.8%. Its beta of 1.05 implies it has historically moved more than the broad market.
Headquartered in Paris, France, Mauna Kea Technologies S.A. commenced operations in 2000. This company specializes in developing and commercializing medical devices, with a broad market presence spanning Europe, the Middle East, Africa, the Americas, and Asia. A primary focus for Mauna Kea Technologies is creating and distributing instruments designed to enable the real-time detection and visualization of cellular irregularities. These innovative tools are utilized during standard endoscopic examinations of the gastrointestinal and pulmonary systems. Their leading product, Cellvizio, stands as a prime example: it is an advanced confocal miniprobe endomicroscopy system. Cellvizio delivers exceptionally detailed, cellular-level images of tissues to both physicians and scientific researchers.
Mauna Kea Technologies S.A. is most often compared with the following Healthcare names: